YYYoomi Yeo

Yoomi Yeo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoomi Yeo has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Trends of Electronic-Cigarette and Heated Tobacco Product Use Among Korean Adults From 2013 to 2023: A Cross-Sectional Study

    by Jong Geol Jang, Sun-Kyung Lee, Sung Jun Chung, Yoomi Yeo, Kyung Soo Hong, Bumhee Yang, Sang Hyuk Kim, Ahn June Hong, Hyung Koo Kang, Tai Sun Park, et al.

    Jang JG, et al. J Korean Med Sci. 2026 Aug;41:e259. https://doi.org/10.3346/jkms.2026.41.e259

  • Open Access

    Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases

    by Chul Park, Yoomi Yeo, A La Woo, Jung Wan Yoo, Goohyeon Hong, Jong Wook Shin, Sung Woo Park, on Behalf of the Korean Interstitial Lung Disease Study Group

    Interstitial lung disease (ILD) comprises a heterogeneous group of disorders characterized by interstitial compartment proliferation, inflammatory infiltration, and potential fibrosis with abnormal collagen deposition. Diagnosis requires a multidisciplinary consensus integrating clinical, radiological, and pathological findings. Idiopathic interstitial pneumonia (IIP) includes idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia, desquamative interstitial pneumonia, acute interstitial pneumonia, and respiratory bronchiolitis-ILD, each exhibiting distinct prognostic and therapeutic implications. Some non-IPF ILDs progress despite standard treatment, classified as progressive fibrosing-ILD or progressive pulmonary fibrosis (PPF), diagnosed by worsening symptoms, physiological decline, and radiological progression. Nintedanib is conditionally recommended for refractory PPF cases. Combined pulmonary fibrosis and emphysema is characterized by upper-lobe predominant emphysema and lower-lobe fibrosis, frequently complicated by pulmonary hypertension and lung cancer. Interstitial lung abnormality, observed in both smokers and the general population, is associated with increased mortality and disease risk, warranting further research. Despite advancements, refinement in classification, diagnostic criteria, and therapeutic strategies remains crucial for improving patient outcomes.


  • Open Access

    Abnormal Brain Functional Connectivity in Patients with Chronic Obstructive Pulmonary Disease and Correlations with Clinical and Cognitive Parameters

    by Kyung-Il Han, Yoomi Yeo, Hang Joon Jo, Min Ju Jo, Yeonkyung Park, Tai Sun Park, Sung Jun Jung, Jin Ho Bae, Sung-Ho Jang, Joonho Choi, et al.

    Background: Cognitive impairment is a major comorbidity of chronic obstructive pulmonary disease (COPD), but the underlying mechanisms are not fully understood. In this study, we used resting-state functional magnetic resonance imaging to investigate brain functional connectivity (FC) abnormalities in patients with COPD and explored the correlation between abnormal FC and COPD-related clinical parameters. Methods: Forty-one patients with COPD, without a definite diagnosis of cognitive impairment or depression, and 30 age- and sex-matched controls were recruited. A total of 184 resting-state functional connectivity (RSFC) maps were generated for all seed points. Welch’s t-test was used to assess differences in RSFC between the COPD and control groups, and the correlation coefficients between RSFC and clinical parameters were calculated. Results: Patients with COPD had lower scores on the Mini-Mental State Exam (MMSE) and Korean version of the Montreal Cognitive Assessment and higher scores on the Beck Depression Inventory than the control group. Additionally, patients with COPD showed decreased RSFC in the left middle-posterior cingulate cortex, left posterior-dorsal cingulate cortex, and right superior occipital gyrus and increased RSFC in the left superior temporal sulcus, left posterior transverse collateral sulcus, right occipital pole, and right precentral gyrus. The regions showing differences in FC correlated with MMSE score, COPD symptom assessment scales, such as the COPD Assessment Test and modified Medical Research Council Dyspnea Scale, and pulmonary function parameters, including forced expiratory volume in one second and forced vital capacity. Conclusion: Patients with COPD showed significant differences in FC within specific brain regions that correlated with symptoms, cognition, and lung function.


  • Open Access

    The Impact of Bronchiectasis on the Clinical Characteristics of Non-Severe Asthma

    by Kyung-Il Han, Hyun Lee, Bo-Guen Kim, Yoomi Yeo, Tai Sun Park, Dong Won Park, Ji-Yong Moon, Sang-Heon Kim, Jang Won Sohn, Ho Joo Yoon, et al.

    Han KI, et al. Allergy Asthma Immunol Res. 2024 May;16(3):291-299. https://doi.org/10.4168/aair.2024.16.3.291


  • Open Access

    The Usefulness of FEF25–75 in Predicting Airway Hyperresponsiveness to Mannitol

    by Youlim Kim, Hyun Lee, Sung Jun Chung, Yoomi Yeo, Tai Sun Park, Dong Won Park, Kyung Hoon Min, Sang-Heon Kim, Tae-Hyung Kim, Jang Won Sohn, et al.

    Background and Objective: Despite the usefulness of airway hyperresponsiveness (AHR) testing in diagnosing and monitoring asthma, it is challenging to perform in a real-world setting. Forced expiratory flow between 25% and 75% of vital capacity (FEF25– 75), a pulmonary measurement that can be obtained easily during routine spirometry, represents the status of medium-sized and small airways. However, the performance of FEF25– 75 in predicting AHR has not been well elucidated. Therefore, we investigated whether FEF25– 75 can predict AHR to mannitol. Methods: We performed a retrospective cohort study of 428 patients who visited a single clinic due to cough, wheezing, or dyspnea. All patients underwent spirometry with a mannitol provocation test. We compared the area under the curve (AUC) of the percentage of the predicted values of FEF25– 75 (FEF25– 75 %pred) with that of forced expiratory volume in 1 second (FEV1%pred), FEV1/forced vital capacity (FVC), and FEF25– 75/ FVC for predicting AHR. Results: The rate of AHR to mannitol was 20.3%. In the overall study population, the AUC of FEF25– 75 %pred for predicting AHR (0.772; 95% confidence interval [CI], 0.729– 0.811) was significantly higher than that of FEV1%pred (0.666; 95% CI, 0.619– 0.710; p < 0.001), FEV1/FVC (0.741; 95% CI, 0.697– 0.782; p = 0.047), and FEF25– 75/FVC (0.741, 95% CI = 0.696– 0.782, p = 0.046). The sensitivity, specificity, positive predictive value, and negative predictive value of FEF25– 75 %pred < 81% for predicting AHR in the overall study population were 77.0% (95% CI = 66.8– 85.4%), 63.9% (95% CI = 58.6– 69.0), 35.3%, and 91.6%, respectively. When we restricted the study group to subjects with normal lung function, the results were similar. Conclusion: Our results indicate that FEF25– 75 %pred can be used as a surrogate for predicting AHR in patients with respiratory symptoms.


  • Open Access

    Short-Acting Beta2-Agonist Use in Asthma in Korea: A 10-Year Population-Based Study

    by Hyun Lee, Jiin Ryu, Sung Jun Chung, Yoomi Yeo, Tai Sun Park, Dong Won Park, Ji-Yong Moon, Tae-Hyung Kim, Jang Won Sohn, Ho Joo Yoon, et al.

    Lee H, et al. Allergy Asthma Immunol Res. 2021 Nov;13(6):945-953. https://doi.org/10.4168/aair.2021.13.6.945


  • Open Access

    Additive Effect of Obesity and Dyslipidemia on Wheezing in Korean Adults: A Nationwide Representative Survey Study

    by Youlim Kim, Hyun Lee, Yeonkyung Park, Sung Jun Chung, Yoomi Yeo, Tai Sun Park, Dong Won Park, Sang-Heon Kim, Tae-Hyung Kim, Jang Won Sohn, et al.

    Kim Y, et al. Allergy Asthma Immunol Res. 2021 Sep;13(5):808-816. https://doi.org/10.4168/aair.2021.13.5.808


  • Body mass index change and incident asthma in adults: A nationwide cohort study

    by Hyun Lee, Hayoung Choi, Hyewon Nam, Bumhee Yang, Bin Hwangbo, Sun‐Young Kong, Sung Jun Chung, Yoomi Yeo, Tai Sun Park, Dong Won Park, et al.